Document is current
Any future updates will be listed below
-
Authors
Pring, Kelly
Malli, Melina https://orcid.org/0000-0003-2744-4034
Hardy, Brandy W. https://orcid.org/0000-0002-0358-3649
Rapp, Stephen R.
Storch, Eric A. https://orcid.org/0000-0002-7631-3703
Mink, Jonathan W. https://orcid.org/0000-0002-7867-3710
Martindale, Jaclyn M. https://orcid.org/0000-0002-4919-8850
-
Funding
Funding for this research was provided by:
Tourette Association of America
- License Information
-
More Information
Article History
Received: 4 September 2023
Accepted: 28 November 2023
First Online: 30 December 2023
Declarations
:
: EAS reports receiving research funding to his institution from the Ream Foundation, International OCD Foundation, and NIH. He was formerly a consultant for Brainsway and Biohaven Pharmaceuticals in the past 12 months. He owns stock less than $5000 in NView. He receives book royalties from Elsevier, Wiley, Oxford, American Psychological Association, Guildford, Springer, Routledge, and Jessica Kingsley. JWM serves as a Central Adjudicator for Emalex; as a DSMB member for PTC; and a consultant for TEVA, Applied Therapeutics, Sumitomo, and Theranexus. He has received research funding from Neurogene and Amicus. JMM receives research support from the Tourette Association of America, the American Board of Psychiatry and Neurology, and the NIH.
